Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Institute of Materia Medica, Chinese Academy of Medical Sciences currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, REYNOLDS, FRED H, within 1 distinct art unit. This concentration of the company's active prosecution under this individual and within a specific technical group indicates a focused review process for the current application.
The identified busiest examiner currently oversees the pending office action. Since there is only a single pending office action in total, REYNOLDS, FRED H is responsible for the entire active workload for the company. This point of contact within the art unit means that the company's immediate patent strategy is dependent on the review of this specific individual.
For practitioners, the focus on a single examiner and art unit simplifies the coordination of the portfolio but also increases the impact of this individual's tendencies. Understanding the examination patterns of REYNOLDS, FRED H will be crucial for navigating the pending office action successfully. The company's current engagement with the patent office is entirely defined by this active matter in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
| VISHNYAKOVA, ELENA VLADIMIROVNA | 1 | 65.8% | +51.3% |
| EBBINGHAUS, BRIANA NOEL | 1 | 61.6% | +63.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17911953 | USE OF EPHB4 AS A TARGET IN SCREENING DRUGS OR MODELS FOR INCREASING INSULIN SENSITIVITY | EBBINGHAUS, BRIANA NOEL | 4d overdue |
| 18860199 | DRUG SUSTAINED-RELEASE TABLET FOR TREATING LIVER DISEASE, PREPARATION METHOD THEREFOR AND USE THEREOF | WHITE, DAWANNA SHAR-DAY | — |
| 18569148 | PYRROLYLACYLPIPERIDYLAMINE COMPOUND AND USE THEREOF | VISHNYAKOVA, ELENA VLADIMIROVNA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17911953 | USE OF EPHB4 AS A TARGET IN SCREENING DRUGS OR MODELS FOR INCREASING INSULIN SENSITIVITY | EBBINGHAUS, BRIANA NOEL | 4d overdue |
| 18860199 | DRUG SUSTAINED-RELEASE TABLET FOR TREATING LIVER DISEASE, PREPARATION METHOD THEREFOR AND USE THEREOF | WHITE, DAWANNA SHAR-DAY | — |
| 18569148 | PYRROLYLACYLPIPERIDYLAMINE COMPOUND AND USE THEREOF | VISHNYAKOVA, ELENA VLADIMIROVNA | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1691 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18860199 | DRUG SUSTAINED-RELEASE TABLET FOR TREATING LIVER DISEASE, PREPARATION METHOD THEREFOR AND USE THEREOF | WHITE, DAWANNA SHAR-DAY | 1629 | §103§112Other | Non-Final OA | — | Pending | Oct 25, 2024 |
| 18569148 | PYRROLYLACYLPIPERIDYLAMINE COMPOUND AND USE THEREOF | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | §102§103 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 17911953 | USE OF EPHB4 AS A TARGET IN SCREENING DRUGS OR MODELS FOR INCREASING INSULIN SENSITIVITY | EBBINGHAUS, BRIANA NOEL | 1632 | §102§112 | Final Rejection | 4d overdue | Pending | Sep 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial